Qube Research & Technologies LTD Bio Atla, Inc. Transaction History
Qube Research & Technologies LTD
- $65.7 Billion
- Q3 2024
A detailed history of Qube Research & Technologies LTD transactions in Bio Atla, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 29,296 shares of BCAB stock, worth $50,389. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,296
Previous 27,220
7.63%
Holding current value
$50,389
Previous $37,000
37.84%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding BCAB
# of Institutions
64Shares Held
17.3MCall Options Held
500Put Options Held
33.5K-
Israel Englander Millennium Management LLC | New York, Ny2.66MShares$4.57 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.52MShares$4.33 Million0.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.89MShares$3.24 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.86MShares$3.2 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA874KShares$1.5 Million0.13% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $62.4M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...